Kamada Ltd Stock Price, News & Analysis

Kamada (NASDAQ: KMDA) announced it will discontinue its Phase 3 InnovAATe trial of inhaled AAT after a prespecified interim futility analysis found the study is unlikely to meet its primary endpoint of lung function (FEV1).

The company said the decision is efficacy‑related and not due to safety concerns, and it will continue supplying GLASSIA (AAT-IV) internationally, including the U.S. and Canada via its licensee TAKEDA. Kamada reiterated its 2025 revenue guidance of $178M–$182M and adjusted EBITDA guidance of $40M–$44M, and projected double-digit revenue and profitability growth in 2026, with detailed guidance to follow in January 2026. Management will host a conference call today at 8:30am ET.

Kamada (NASDAQ: KMDA) reported strong Q3 and nine-month 2025 results, with Q3 revenue $47.0M (+13% YoY) and Q3 adjusted EBITDA $11.7M (+34% YoY). Nine-month revenue was $135.8M (+11% YoY) with adjusted EBITDA of $34.2M (+35% YoY). The company generated $17.9M cash from operations in the first nine months and held $72.0M cash as of Sep 30, 2025. Kamada reiterated full-year 2025 guidance of $178M–$182M revenue and $40M–$44M adjusted EBITDA. Key operational updates: FDA approval for Houston plasma center, launch of the SHIELD CYTOGAM investigator study, and an interim futility analysis for the InnovAATe Phase 3 trial due this quarter.

Kamada (NASDAQ: KMDA) announced on November 4, 2025 that the first patient was enrolled in an investigator-initiated, post-marketing randomized controlled multicenter trial named SHIELD testing CYTOGAM (Cytomegalovirus Immune Globulin Intravenous) to prevent late CMV disease in high-risk kidney transplant recipients (donor CMV seropositive / recipient seronegative).

The study will evaluate CYTOGAM dosed at the end of standard antiviral prophylaxis to reduce clinically significant late CMV; it is led by Camille Kotton, M.D., and David Wojciechowski, D.O. The release notes that up to one third of kidney transplant patients may develop late CMV after stopping prophylaxis.

Kamada (NASDAQ: KMDA) will release its third quarter and nine months ended September 30, 2025 financial results on Monday, November 10, 2025 before U.S. market open. Management will host an investor conference call on November 10, 2025 at 8:30 AM Eastern Time to discuss results and answer questions.

Shareholders can join by phone using conference ID 13756537 (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) or listen via live webcast at https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.

Kamada (NASDAQ: KMDA) announced that Amir London, Chief Executive Officer, will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 9:20 a.m. ET at the Lotte New York Palace Hotel in New York.

Mr. London will also be available for one-on-one investor meetings throughout the conference; investors should arrange meetings through their Stifel representative. A live webcast of the presentation will be available via the company-provided link.

Kamada (NASDAQ: KMDA), a global biopharmaceutical company specializing in rare conditions and specialty plasma-derived products, announced its participation in two major investor conferences in September 2025.

CEO Amir London will present at the Wells Fargo Healthcare Conference on September 3, 2025, at 3:45 PM ET, and the H.C. Wainwright Global Investment Conference on September 8, 2025, at 11:00 AM ET. One-on-one investor meetings will be available at both conferences, with live webcasts accessible through provided links.

Kamada (NASDAQ: KMDA) reported strong financial results for Q2 and H1 2025, with significant growth in both revenue and profitability. First half 2025 revenues reached $88.8 million, up 11% year-over-year, while Q2 revenues were $44.8 million, a 5% increase. The company's adjusted EBITDA for H1 2025 grew 35% to $22.5 million, representing a 25% margin.

Based on robust performance, Kamada raised its 2025 adjusted EBITDA guidance to $40-44 million and maintained revenue guidance of $178-182 million. The company received FDA approval for its Houston plasma collection center, with an estimated annual revenue potential of $8-10 million at full capacity. Additionally, Kamada continues to advance its Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy.

Kamada Ltd. (NASDAQ: KMDA) has received FDA approval for its plasma collection center in Houston, Texas, allowing commercial sales of normal source plasma. The 12,000 square foot facility features 50 donor beds with an annual collection capacity of 50,000 liters of plasma.

The Houston center, positioned to be one of the largest specialty plasma collection sites in the U.S., is expected to generate $8-10 million in annual revenue at full capacity. The facility will collect both normal source plasma and specialty plasma, including Anti-Rabies and Anti-D. This marks Kamada's third Texas-based site, alongside locations in San Antonio and Beaumont.

Kamada (NASDAQ: KMDA), a commercial stage biopharmaceutical company specializing in rare and serious conditions through plasma-derived products, has scheduled its Q2 and H1 2025 financial results announcement for August 13, 2025, before U.S. markets open.

The company will host an investment community conference call at 8:30 AM ET on the same day, where management will discuss results and take questions. Investors can join via phone or webcast, with specific dial-in numbers provided for U.S., Israeli, and international participants.